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Abstract 
Abstract 
Review on der(1;7)(q10;p10), with data on clinics 
and cytogenetics. 
Clinics and pathology 
Note 
Preponderant in myeloid disorders. 
Disease 
Myelodysplasic syndromes (MDS) in 60 % of 
cases.  
Acute myeloid leukemia (AML) in 30%, most 
commonly AML-M2 but reported in all FAB 
subtypes; frequently with preceeding MDS.  
Myeloproliferative neoplasms (MPN) represent 
the remaining 10% of cases.  
Lymphoid disorders: very rare, half of cases being 
multiple myeloma with the der(1;7) as the sole 
abnormality (raising the possibility of an underlying 
MDS), the other half in various lymphoid disorders 
chronic lymplocytic leukemia (CLL), Burkitt 
lymphoma/leukemia, follicular lymphoma), most 
often part of a complex karyotype (Geisler et al., 
1997; Hsiao et al., 2005; Al-Bahar et al., 2010). 
Others: reported in only one case each of bilineage 
or biphenotypic acute leukemia with a t(9;22) 
(Sanada et al. 2007), sarcoma (Roberts et al., 2008) 
and carcinoma (Jin et al., 2002) with complex 
karyotypes and in two cases of aplastic anemia (Kim 
et al., 2010). 
Phenotype/cell stem origin 
MDS cases: most commonly RA (60%).  
AML cases: most commonly M2 but has been 
reported in all FAB subtypes.  
MPN cases: reported in a few cases of polycythemia 
vera, essential thrombocythemia, chronic 
myelomonocytic leukemia and idiopathic 
myelofibrosis. 
Epidemiology 
Found in 1.5-6% of MDS, 0.2-2% of AML and 
rarely in MPN. Older adults mostly (median late 
50's, early 60's. male predominance (4M/1F), 
influenced partly by the preponderance of males in a 
large study of Japanese MDS cases with der(1;7) 
(Sanada et al., 2007). 
Prognosis 
MDS: There is some controversy as to the prognosis 
of the der(1;7) with trisomy 1q and monosomy 7q. A 
better outcome of der(1;7) compared to -7/del(7q) 
cases was shown in a retrospective study including 
77 cases (Sanada et al., 2007), while there was no 
statistical difference in overall survival between 
der(1;7) versus del(7q) versus -7 in several studies 
including a smaller number of patients (Slovak et al., 
2009; Hussain et al., 2012).  
AML: In the UKMRC trials, the der(1;7) may be 
included in the "-7/del(7q)" group, associated with a 
poor prognosis (Grimwade et al., 2010). In the 
CALGB 8461 study, loss of 7q was associated with 
an intermediate prognosis (Byrd et al., 2002). 
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Unbalanced whole-arm translocation with two 
chromosomes 1, a derivative chromosome including 
the long arm of chromosome 1 and the short arm of 
chromosome 7, and a chromosome 7 resulting in 
trisomy for 1q / monosomy for 7q. The balanced 
form may have been reported once in a secondary 
AML-M2 case (Higuchi et al., 1995). 
Additional anomalies 
85% of cases are not complex if the unbalanced 
der(1;7) with extra chromosome 1 is considered as a 
single abnormality ("single abnormality" in 50% of 
cases, one additional abnormality in the remaining 
35%). The most frequent additional abnormalities 
are: +8 (50%); del(20q) (20%); +21 or +9 (3% each).  
A cytogenetically unrelated, abnormal clone is found 
in 5% of cases, 80% in MDS, 20% in AML. Loss of 
Y, -7 and +8 are the most common abnormalities. 
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